Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (15980)	8/15/2002 2:26:47 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Bax already spent lots of $ in the Fda rejected meningo indication of Neuprex. They gave xoma ~$15M (the whole trial expenses?) is a significant amount. The division or vicepresident that deal with xoma and Neuprex MAYBE is on a hot seat, careful not to dump another big chunk of $ the xoma way and end his/her career. Plus bax is a large corporation with tons of projects, the most advance with commercial prospects are the first, neuprex is on a backseat in standstill. Remember the bax when crazy in one CC with the $500M prospects for bpi and never to mentioned it again. Corporations may mistakes like Bmy going all the way with Erbitux, or J&J abandoning good drugs programs that did well later. Bax seems to be very reticent with failures (different to mmmhhhullen!), and they like to pick carcasses (NVA plant and intelectual property) same way they pick the hemophilia business, the allp drug is on delay due to their paucity of funding (contract was tougher), and look at xoma bpi palsy. It seems to be the Bax way of handling risks, SINTGY to the max!